Apr. 29 at 4:42 PM
NEURO BIOTECH + AI DRUG DISCOVERY 👇
$GANX
Been keeping an eye on Gain Therapeutics — they're using their Magellan AI platform to go after the root cause of Parkinson's, not just the symptoms. Their lead drug GT-02287 works by restoring a key enzyme (GCase) that breaks down in PD patients.
What's standing out:
🔹 Phase 1b showed an 81% avg drop in a key PD biomarker — first time ever seen with a GCase drug
🔹 Patients still showing stable motor scores at 5 months of dosing
🔹 They doubled their cash to
$20.8M — funded through end of 2026
🔹 FDA Phase 2 IND expected Q2 → U.S. trial kicking off Q3 2026
🔹 Next-gen compound GT-04686 already prepped for the next stage
Their pipeline stretches into Alzheimer's, Gaucher's, and Oncology — and the AI platform keeps generating new candidates.
Big catalysts coming in the back half of 2026. One to watch.
Communicated Disclaimer - DYOR.
https://chartingdaily.com/structural-health
Other neuro biotechs moving:
$DNLI $BIVI $XENE $ANVS